© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Cefepime sits as a fourth-generation cephalosporin, first discovered during the fevered pace of antibiotic innovation in the late twentieth century. Back then, the field looked for broad-spectrum solutions due to rising resistance. Scientists pushed cephalosporin chemistry past earlier boundaries and eventually, Cefepime’s unique structure broke onto the scene. Researchers combined lessons from the first and third generations, blending stability against β-lactamases and a broadened reach against both Gram-positive and Gram-negative bacteria. Regulatory filings in Europe and North America during the early 1990s transformed Cefepime into a frontline hospital tool. From that point, the ability to treat serious infections like pneumonia and sepsis solidified its place within critical care protocols, especially as ICU resistance issues grew increasingly dire.
Hospitals keep Cefepime Hydrochloride close at hand for its broad activity against organisms like Pseudomonas aeruginosa and Enterobacter. The drug’s powder form dissolves easily for injection, a real advantage for time-pressed clinicians. Manufacturers focus on producing highly purified, sterile batches due to strict standards demanded by both FDA and EMA markets. Healthcare settings rely heavily on antibiotics with strong track records—Cefepime doesn’t just hold regulatory approval, but also stacks up over decades of clinical use, especially under pressure from growing multidrug resistance. In day-to-day hospital life, pharmacists, nurses, and infection control teams see the drug not as some abstract tool, but as a key defense against life-threatening infections in vulnerable patients.
Cefepime Hydrochloride appears as a white or pale yellowish crystalline powder. Water dissolves it without difficulty, crucial for hospital use, since fast administration often marks the difference between recovery and decline for critically ill people. With a molecular weight of about 571.5 g/mol (as the hydrochloride salt), this cephalosporin hydrolyzes in alkaline solutions, which can impact storage. Chemically, the structure packs a β-lactam ring and a syn-configuration at the methoxyimino group—this tweak shields it from many β-lactamases that would break down older cephalosporins, giving Cefepime a vital edge in today’s resistance-focused climate.
Cefepime Hydrochloride must meet specifications for identity, potency, purity, and sterility set by global pharmacopeias. U.S. and EU rules require expiration dating that reflects degradation kinetics in standard hospital storage conditions. Containers list both base drug content and calculated amount as hydrochloride for accurate dosing. Labels warn of potential allergic reactions, especially in patients with a penicillin history, and spell out instructions for both storage and reconstitution. Pharmacovigilance demands QR codes and lot numbers for traceability through every stage of healthcare supply chains. Technical documentation tracks preparation methods, batch records, and stability data, giving end-users assurance of consistent, validated performance.
For production, fermentation of a cephalosporin-producing microorganism forms the backbone. Enzymatic step-wise modification and precise chemical reactions introduce the methoxyimino group and the aminothiazolyl moiety. Manufacturers control pH, temperature, and timing to funnel the process toward a high-yield, low-impurity outcome. Final purification involves crystallization, filtration, and lyophilization to protect the β-lactam core. Sterile filling lines need meticulous cleaning and validation. Regulatory inspections dig into every step, from upstream ingredient sourcing through post-market surveillance. Handling the product outside of the lab demands skill, as β-lactams are notoriously sensitive to heat and pH changes, and every spoiled batch means lost time and fewer options for sick patients.
Cefepime’s chemical synthesis hinges on the stability of its β-lactam ring, susceptible to both acid and basic hydrolysis. Development teams made modifications at the 7-position side chain, installing an aminothiazolyl imine for enhanced Gram-negative activity. Efforts to further modify this structure have looked at creating analogues to evade evolving β-lactamase families. While bioconjugation strategies attract attention for longer-acting injectable forms, real-world batch chemistry chases ever higher purity and recovery rates, since every impurity risks a potentially severe reaction in fragile patients. No major direct metabolite achieves the same broad adoption, though research lines keep probing new cephalosporin scaffolds using Cefepime as a chemical model.
Some in the field call it Cepimax, Maxipime, Cefepime dihydrochloride, or even Hydrochloride salt of Cefepime. Hospital buyers and pharmacists scan for names like Axepim, Neopime, and Cepimex, depending on market. CAS Registry assigns it the number 123171-59-5 for exact identification. Synonyms help bridge international conversations, but hospitals—regardless of the label—treat it as a mainstay for severe infections.
Healthcare workers have learned best practices from both accident and experience. Accidental exposure—whether in compounding, needle sticks, or spills—demands swift cleanup and attention, since β-lactams can cause severe allergic reactions in sensitive individuals. Occupational protocols cover gloves, eye protection, and closed-system transfer devices. Safe disposal instructions are written into drug monographs and hospital SOPs, ensuring leftover solution and vials stay out of the waste stream. This drug’s power in the body means a small mistake during its preparation or administration can drive serious consequences, so hospitals train staff repeatedly, using both live drills and digital modules.
Critical care teams lean on Cefepime Hydrochloride for hospital-acquired infections, particularly those from resistant strains of Gram-negative bacteria. The scope includes pneumonia, intra-abdominal infections, febrile neutropenia in cancer patients, and severe urinary tract infections. In emergency settings, its rapid onset and broad coverage give it priority for empiric regimens, especially before pathogen identification. Field clinicians, pediatricians, and oncologists each tell stories of Cefepime swinging the tide against septic shock, giving vulnerable patients a fighting chance. Sometimes, infectious disease experts choose it for its reliable pharmacokinetics, making it easier to manage dosing even in patients with fluctuating renal function or on continuous renal replacement therapy.
R&D groups scrutinize Cefepime’s mechanism against new resistance genes, especially extended-spectrum β-lactamases (ESBLs) and emerging carbapenemases. Teams profile its action in animal models, study dosing adjustments for renal failure, and investigate interplay with other antimicrobials. In the fight against increasingly tough hospital superbugs, bench scientists engineer analogues building off the Cefepime framework, seeking either longer action or less susceptibility to hydrolysis. University labs probe its pharmacodynamics, aiming for better combination therapy strategies. All this work feeds back into the hospital, informing guidelines, and making sure protocols stay up to date with evolving threats. The complexity of bacterial resistance keeps researchers on their toes, pushing for methods to safeguard Cefepime’s effectiveness for future generations.
Doctors and nurses recognize the value of Cefepime, but they also face its risks head-on. Neurotoxicity stands out as a concern, especially in older or renally impaired patients—confusion, seizures, and encephalopathy have been reported when levels accumulate. Labs monitor blood and kidney parameters closely, adjusting dosing as needed to minimize risk. Infusion site phlebitis, gastrointestinal upset, and allergic reactions round out the principal risks described in both clinical trial data and real-world use. Antimicrobial stewardship programs push staff to stay alert for subtle early signs, since prompt dose adjustment or discontinuation keeps problems from snowballing. Rather than letting guidelines grow stale, stewardship programs gather and analyze post-market safety trends, creating living documents that adapt alongside emerging data.
Cefepime Hydrochloride stands at a crossroads as resistance mechanisms threaten to undercut even advanced β-lactam agents. While big pharma eyes the next generation, pragmatic hospital teams focus on extending Cefepime’s peak years—optimizing dosing, developing rapid diagnostics, and pairing with new β-lactamase inhibitors. Future versions might use depot injections or oral delivery forms, but today, the real action happens in stewardship and combination therapy studies. The ongoing push for personalized dosing based on pharmacogenetics and renal function charts a new direction for critical care. On the regulatory front, harmonized guidelines help prevent overuse, keeping Cefepime in the toolkit for as long as possible. The push to integrate surveillance data and resistance trends directly into clinical decision support shows one path forward, tying together innovation and patient care in one cooperative loop.
Every year, hospitals take in thousands of patients facing barely controlled infections. Doctors rely on antibiotics that can break tough bacteria. Cefepime Hydrochloride stands out. It gets used for treating hospital-acquired infections like pneumonia, especially those caused by bacteria that don’t back down easily. The bugs found in these settings often laugh at older medicines, so having something like cefepime at the doctor’s disposal makes a difference. Hospitals keep this antibiotic ready because it can target bacteria that have built shields (called beta-lactamases) to protect themselves from other drugs.
Bacterial infections in the blood—sepsis—don’t give much time. I’ve seen in practice how quickly patients can slide downhill. Cefepime finds use against sepsis, whether the source is the lungs, urinary tract, or elsewhere. Doctors appreciate cefepime’s reach; it can hit many bacteria at once, including certain strains of Pseudomonas. These bacteria often shrug off basic antibiotics. In my experience, speed saves lives, and having access to cefepime allows for action even before a lab report nails down the exact bug.
Folks who have weakened immune systems, like those undergoing chemotherapy, often walk a tightrope. A simple infection can become deadly fast. Cefepime works against the spectrum of bacteria that tend to strike when the immune system sits on the sidelines. Cancer patients often receive cefepime as soon as they run fevers, long before anybody knows what’s growing in their blood, because waiting isn’t an option. The Infectious Diseases Society of America pushes this antibiotic to the front for febrile neutropenia—basically, fevers in patients with low white cell counts.
Not every infection fits in a neat box. Sometimes patients walk through the emergency room doors with complicated infections—like abdominal infections after surgery. Instead of throwing three or four drugs at the problem, cefepime often provides a single-hit approach, cleaning up a wide range of bacteria. Prescribers have to watch for side effects, like confusion in elderly or kidney-compromised patients. Nobody wants to swap one problem for another, so monitoring during therapy becomes key.
There’s a downside to powerful antibiotics like cefepime. Overuse breeds resistance. Once bacteria get smart, every future patient stands to pay the price. Health care workers balance the need for broad protection against the risk of losing this tool for good. Simple stewardship steps—only prescribing cefepime when other options fail, stopping it if a culture shows a weaker bug—help keep resistance in check. Having seen the wave of resistance rise with other drugs, I believe careful choice beats indiscriminate prescribing every time.
Cefepime Hydrochloride plays a critical role in the hospital arsenal, especially for the sickest and most vulnerable. Its strength matters most in life-or-death battles where waiting isn’t an option. Success depends on respect for what antibiotics can do and discipline in not reaching for them out of habit. No matter how advanced medicine gets, thoughtful use and honest conversations about risk and reward usually point the way forward.
Cefepime Hydrochloride can save lives, especially in hospitals when infections get aggressive. Like many antibiotics, it brings along risks that anyone using it should understand. Common side effects hit the gut first—nausea, diarrhea, and stomach pain lead the list. I’ve seen folks in clinic come in thinking their infection’s gone, but then struggle with stomach cramps or loose stools. These issues deserve attention, since persistent diarrhea means something more serious might be brewing, such as a Clostridioides difficile infection.
Allergies can hit out of the blue. Someone who’s never reacted to a medicine before might break out in hives, struggle to breathe, or see their face and throat swell after taking cefepime. These problems need immediate medical care. People who have reacted badly to penicillins or other cephalosporins should tell their doctor before starting cefepime, since cross reactions happen more often than people think.
One of the scarier problems I’ve heard about involves the nervous system. In rare cases, especially in people whose kidneys don’t clear drugs well, cefepime can trigger confusion, hallucinations, or even seizures. Seniors or people with kidney disease face the highest risk. Sometimes these symptoms get mistaken for worsening illness, dementia, or simple stress, leading to dangerous delays in care. It helps to know that even subtle confusion or agitation after starting this drug might point back to it, especially when paired with kidney problems.
Antibiotics sometimes mess with the skin. I’ve seen patients develop rashes, flushing, and in severe cases, peeling skin and blistering from reactions like Stevens-Johnson syndrome. Thankfully, these are rare, but they’ve left deep marks on patients and families. Blood counts can also take a hit. Cefepime has caused low white cells, platelets, or even anemia in some cases. Routine blood tests help catch these surprises before they spiral.
Beyond numbers and warnings, people using cefepime report tiredness, headaches, or odd tastes in the mouth. Sometimes these frustrations feel minor, but they wear folks down, especially in the middle of a tough illness. Knowing what could pop up during treatment lets patients and families push for answers earlier, rather than waiting for things to get worse.
Talking openly about allergies, kidney problems, and other medications helps healthcare teams decide when cefepime makes sense—and when safer choices exist. Regular lab checks spot problems with white cells, platelets, or kidney function before symptoms even show. If stomach issues hit hard, doctors might recommend probiotics or alternatives to support gut health. Acting on side effects early can mean switching drugs, lowering doses, or ramping up monitoring. By looking for small changes—mental fogginess, rashes, persistent stomach upset—patients and caregivers help catch trouble while it's still early.
Staying informed isn’t just about reading a pamphlet. People do better when they know what to expect and when to speak up. Reporting symptoms, asking about side effects, and understanding risks lead to better outcomes for everyone involved.
Administering Cefepime Hydrochloride is more than just drawing up a syringe. This isn’t lost on any nurse who has answered a 2 am call with sepsis in the room or a doctor weighing the next step for a patient who’s flaring up. Cefepime can take out a broad range of bacteria, but folks who use it will tell you: one slip in the way of preparing, dosing, or delivering it changes everything.
Most of the time, Cefepime goes in through an intravenous drip. There’s also the option for intramuscular shots, but veins are usually the road taken, especially for the sickest patients. Direct IV push or slow infusion—both have a place, but speed matters. Run it in too fast, and the risk for neurological effects climbs, especially in people whose kidneys don’t clear drugs the way they used to.
You mix Cefepime with the right amount of sterile water or saline. Rushing through that step invites pain or complications right at the injection site. Some nurses have stories where improper mixing caused bumps, bruises, or a screaming infusion pump that refused to play along. The specifics depend on the hospital guidelines, but a common approach is using about 10 mL of diluent for each gram if going IV. No one wants a gritty residue left behind, so mixing until fully dissolved is a must.
Dosing depends on who’s in the bed. An adult with healthy kidneys ends up with a different regimen compared to someone in their eighties, or someone with renal failure. Not enough medicine, and the infection bullies its way back. Too much, and patients face real trouble—confusion, twitching, in rare cases, seizures. For anyone with kidney problems, the dose gets cut and the timing between doses stretched out. This is about listening to lab results and trust in experience: a tired nurse, a hundred charts deep, stops and confirms kidney function before pressing start on the infusion.
Sticking to the schedule blocks bacteria from regrouping. Lateness, skipping a dose, or doubling up after a miss can mean the difference between a good story and a disaster. Hospitals live by these little windows of time for a reason. It’s extra work, but setting reminders, using medication cards, or checking off charts builds that safety net.
Reactions, though rare, happen. Patients sometimes develop rashes, trouble breathing, or gut upsets. It’s on the caregiver to ask, listen, and watch, especially right after the first few doses. Folks with allergies—especially to penicillins or other cephalosporins—get a bit more extra care.
Antibiotic resistance adds another layer. One mistake, and bacteria learn new tricks, dodging the very drugs meant to knock them out. This isn’t just about rules on paper. It’s bodies in beds, families in waiting rooms, and the silent math of what works and what doesn’t. Many places now have stewardship programs, reminding everyone to question, track, and double-check every prescription.
Delivering Cefepime Hydrochloride isn’t just a technical skill. It’s the weight of every decision, the cost of a shortcut, and the difference a sharp eye can make. Patients trust that what drips into their veins is right. Healthcare teams, with facts, focus, and a lot of hard-won routine, work to make sure it stays that way.
Cefepime hydrochloride shows up on prescription pads in hospitals and clinics when doctors need strong antibiotics for tough infections. Sometimes it feels like an easy choice for doctors—quick, potent, fights what others can’t. Still, those getting this drug deserve a good look at what it can and can’t do. Healthcare isn’t just about giving what’s available; it’s about making sure the medicine offered really fits the person taking it.
Some people walk into a hospital carrying an allergy list longer than their medication list. If someone has a reaction history to cephalosporins, penicillins, or other beta-lactam antibiotics, cefepime isn’t a great pick. Cross-reactivity isn’t just a textbook concept—I’ve seen folks break out in hives after a single dose because the lesson wasn’t learned. The consequences? Full-blown anaphylaxis in unlucky cases. No one wants to code over an antibiotic.
Cefepime leaves the body through the kidneys. So anybody with kidney disease, whether they know it or not, faces extra risk. The drug can build up to toxic levels. It doesn’t just mean sticky lab results—patients get confused, drowsy, and sometimes fall into seizures. The FDA’s warning about non-convulsive status epilepticus in people getting too much cefepime isn’t theoretical. The dosage should match the kidney’s performance, and doctors don’t always check creatinine before another bag starts dripping.
Aging turns the body’s filter system slower and weaker. Older adults run a higher chance of trouble, even if nobody called them “kidney patient” yet. Multiple medications, dehydration, and a fading memory of telling their doctor everything play into the risk. I’ve met patients who didn’t realize antibiotics can push their bodies over the edge. For these folks, routine dose and frequency checks must become the rule, not the exception.
Long antibiotic courses with broad drugs like cefepime don’t just threaten the patient—they stir the pot for the whole hospital. I watched hospitals struggle with C. difficile outbreaks, often traced back to repeated or prolonged use of antibiotics like cefepime. Superinfections, the rise of resistant bugs, and gut complications create headaches for everyone. Prescribers do better by keeping the course as short as possible and switching to narrow options when culture results come back.
Checking allergies, reviewing medications, watching kidney numbers—these steps feel basic, but overworked teams sometimes miss them. Pharmacists, nurses, and specialists should get involved before someone lands in trouble. Communication between patient and healthcare provider makes a huge difference too. I’ve seen problems avoided just because someone double-checked a lab result or asked about past rashes and breathing issues.
Guidelines say cefepime shouldn’t go out without double-checking allergies and kidney function. Care teams need electronic systems that flag high-risk patients. Education for frontline staff and patients goes further than any warning label. Shorter antibiotic courses, careful dose adjustments, and a culture of asking questions keep people safer.
If a doctor talks about Cefepime Hydrochloride around someone who’s pregnant or breastfeeding, plenty of questions show up quick. The label on this drug might not always bring comfort: research doesn’t cover every situation, and answers don’t just fall into your lap from the pharmacist’s leaflet.
Cefepime lands in the fourth generation of cephalosporin antibiotics. Hospitals pull it out when serious bacterial threats walk through the door. Doctors have to weigh risk versus reward. The animal studies haven’t flagged up birth defects or surprises in fetal growth. Still, no one wants to lean on results from rats when making decisions for humans. The FDA dropped its old letter grades, but Cefepime used to sit as a Category B—no proof of harm in animal studies, but not enough data from pregnant women to breathe easy.
Many infection specialists have watched women go through pregnancy with Cefepime on board, especially during life-threatening infections. Their experience lines up with the numbers: there haven’t been spikes in birth problems from its use. That said, everyone pays extra attention. Doctors check what other options exist, and Cefepime only stays on the roster if the illness would put both mother and baby at greater risk than the drug ever could.
Moms nursing newborns always want straight answers on safety. Cefepime can end up in breast milk. The studies so far suggest that only small amounts pass over. Experts haven’t seen a wave of problems—no fussing or odd symptoms in infants, and no routine reports of bad reactions. Still, infants are small, and their gut flora and immature kidneys bring extra sensitivity. A dose meant for a big person looks a bit different to a tiny belly, even if what reaches them is tiny.
Just because research doesn’t show a big problem doesn’t mean the decision gets easy. Healthcare professionals know how torn families feel—nobody wants to take chances with a baby’s health, born or unborn. Open talks matter more than rigid protocol. Women need space to ask and weigh up what feels right. Care runs deeper than matching patients to drug charts.
The real test: does the infection risk outweigh what might happen with the drug? Sepsis, lung infections, and stubborn urinary tract infections all can threaten a mom’s life. Failing to treat that puts everyone at even more risk. So, doctors keep a close eye, track the baby, and talk over every sign along the way.
Many families get stuck waiting for perfect answers. Government health bodies and hospitals should keep collecting and sharing more up-to-date safety records—especially for antibiotics that step in during emergencies. Pharmacists can help nurses and families spot any changes in the baby during breastfeeding, and make adjustments as soon as possible. More research funding can fill the gaps in knowledge, so parents and providers walk into decisions with more light and less guesswork.
Every choice draws on trust. Nobody can promise zero risk, but honest, experience-backed guidance gives new and expectant mothers the power to face infection treatment without extra fear clouding the picture.
| Names | |
| Preferred IUPAC name | (6R,7R)-7-[2-(2-Aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydrochloride |
| Other names |
Cefepime HCl Cefepimum hydrochloridum Cefepime dihydrochloride Cefepime hydrochloride hydrate |
| Pronunciation | /sɛˈfiːpiːm haɪˌdrɒklaɪd/ |
| Identifiers | |
| CAS Number | “123171-59-5” |
| Beilstein Reference | 79162 |
| ChEBI | CHEBI:59756 |
| ChEMBL | CHEMBL2106101 |
| ChemSpider | 16843973 |
| DrugBank | DB01413 |
| ECHA InfoCard | 03bea8ab-c0ea-4338-a45c-d607aausbb27 |
| EC Number | 130718-25-3 |
| Gmelin Reference | 3248389 |
| KEGG | D03631 |
| MeSH | D000077321 |
| PubChem CID | 6918499 |
| RTECS number | RK2675000 |
| UNII | R745RUV927 |
| UN number | UN3249 |
| Properties | |
| Chemical formula | C19H24ClN6O5S2 |
| Molar mass | 517.92 g/mol |
| Appearance | White to pale yellow crystalline powder |
| Odor | Odorless |
| Density | 1.92 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -1.5 |
| Acidity (pKa) | 2.5 |
| Basicity (pKb) | pKb: 6.6 |
| Magnetic susceptibility (χ) | -78.5×10⁻⁶ cm³/mol |
| Viscosity | Viscous liquid |
| Dipole moment | 2.86 D |
| Pharmacology | |
| ATC code | J01DE01 |
| Hazards | |
| Main hazards | May cause allergic reactions; contact with product may cause irritation to skin, eyes, and respiratory tract. |
| GHS labelling | GHS07, GHS05 |
| Pictograms | GHS05, GHS07 |
| Signal word | Warning |
| Hazard statements | Hazard statements: H302, H315, H319, H335 |
| Precautionary statements | Keep out of reach of children. For professional use only. Use aseptic technique. Discard unused portion. Store at controlled room temperature. Do not use if solution is discolored or contains particulate matter. |
| NFPA 704 (fire diamond) | 1-0-0-W |
| Flash point | > flash point > 110°C |
| Lethal dose or concentration | LD50 (mouse, IV): 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): 2339 mg/kg (intravenous, mouse) |
| PEL (Permissible) | PELL: Not established |
| REL (Recommended) | IV: 2 g every 8 hours |
| Related compounds | |
| Related compounds |
Cefepime Cefpirome Ceftriaxone Cefotaxime Ceftazidime |
